Madelyn Moore
Overview
Explore the profile of Madelyn Moore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vile R, Pulido J, Chen A, Kendall B, Tonne J, Metko M, et al.
Res Sq
. 2024 Nov;
PMID: 39606441
T cell immune tolerance is established in part through the activity of the Auto-immune Regulator (AIRE) transcription factor in the medullary Thymic Epithelial Cells (mTEC) of the thymus. AIRE induces...
2.
Webb M, Sangsuwannukul T, van Vloten J, Evgin L, Kendall B, Tonne J, et al.
Nat Commun
. 2024 Jun;
15(1):5442.
PMID: 38937436
Although patients benefit from immune checkpoint inhibition (ICI) therapy in a broad variety of tumors, resistance may arise from immune suppressive tumor microenvironments (TME), which is particularly true of hepatocellular...
3.
Fisher C, Johnson K, Moore M, Sadrati A, Janecek J, Graham M, et al.
Diabetes
. 2024 May;
73(8):1244-1254.
PMID: 38776417
Article Highlights:
4.
Vile R, Webb M, van Vloten J, Evgin L, Sangsuwannukul T, Kendall B, et al.
Res Sq
. 2023 Dec;
PMID: 38045348
Although immune checkpoint inhibition (ICI) has produced profound survival benefits in a broad variety of tumors, a proportion of patients do not respond. Treatment failure is in part due to...
5.
Smith K, Peng K, Pulido J, Weisbrod A, Strand C, Allred J, et al.
Front Immunol
. 2023 Nov;
14:1279387.
PMID: 38022659
Introduction: Metastatic uveal melanoma (MUM) has a poor prognosis and treatment options are limited. These patients do not typically experience durable responses to immune checkpoint inhibitors (ICIs). Oncolytic viruses (OV)...
6.
Fisher C, Johnson K, Moore M, Sadrati A, Janecek J, Graham M, et al.
bioRxiv
. 2023 Sep;
PMID: 37732180
During diabetes, β-cell dysfunction due to loss of potassium channels sensitive to ATP, known as K channels occurs progressively over time contributing to hyperglycemia. K channels are additionally present in...
7.
Webb M, Kottke T, Kendall B, Swanson J, Uzendu C, Tonne J, et al.
Mol Ther Oncolytics
. 2023 Jun;
29:129-142.
PMID: 37313455
In multiple models of oncolytic virotherapy, it is common to see an early anti-tumor response followed by recurrence. We have previously shown that frontline treatment with oncolytic VSV-IFN-β induces APOBEC...
8.
Evgin L, Kottke T, Tonne J, Thompson J, Huff A, van Vloten J, et al.
Sci Transl Med
. 2022 Apr;
14(640):eabn2231.
PMID: 35417192
Oncolytic viruses (OVs) encoding a variety of transgenes have been evaluated as therapeutic tools to increase the efficacy of chimeric antigen receptor (CAR)-modified T cells in the solid tumor microenvironment...
9.
Okerman T, Jurgenson T, Moore M, Klein A
Mol Pain
. 2021 Mar;
17:17448069211003375.
PMID: 33745380
Research presented here sought to determine if opioid induced tolerance is linked to activity changes within the PI3Kγ-AKT-cGMP-JNK intracellular signaling pathway in spinal cord or peripheral nervous systems. Morphine or...
10.
Fisher C, Johnson K, Okerman T, Jurgenson T, Nickell A, Salo E, et al.
Front Neurosci
. 2019 Nov;
13:1122.
PMID: 31695594
ATP-sensitive potassium (K) channels are found in the nervous system and are downstream targets of opioid receptors. K channel activity can effect morphine efficacy and may beneficial for relieving chronic...